

**Meir Bialer, PhD, MBA, is the David H. Eisenberg Professor of Pharmacy at the School of Pharmacy, Faculty of Medicine of The Hebrew University of Jerusalem. He received his B.Pharm (with distinction), M.Sc. (with distinction), M.B.A. and Ph.D. degrees from The Hebrew University of Jerusalem. Dr. Bialer completed a postdoctoral fellowship in pharmacokinetics at the University of Florida and spent an additional year at the College of Pharmacy at the University of Kentucky. Since 1980 he has been a member of the faculty of the School of Pharmacy of The Hebrew University of Jerusalem and from 1994-1997 served as Head of the Department of Pharmaceutics in the School of Pharmacy. Professor Bialer has been awarded the Fellow (1992) of the American Association of Pharmaceutical Scientists (AAPS), Kaye Innovation Award (2000) of The Hebrew University of Jerusalem, an Ambassador for Epilepsy Award (2001) of The International League Against Epilepsy (ILAE) and The International Bureau for Epilepsy (IBE). He is also the co-founder and member of the Organizing Committees of the twelve (1992-2014) EILAT Conferences on New Antiepileptic Drugs, the five Eilat International Educational Courses on the Pharmacological Treatment of Epilepsy (2005-2013) and the four (1988-1999) Jerusalem Conferences on Pharmaceutical Sciences and Clinical Pharmacology. He is a former president of the Israeli Society of Clinical Pharmacy and Biopharmaceutics (1989-1999) and of the Israeli League Against Epilepsy (1996-2002). He has served or is currently serving as a member of the editorial board of the following international journals: Biopharmaceutics & Drug Disposition (1988-2012), CNS Drugs (1994-present), Epilepsia (2000-2010), Epilepsy & Behaviour (2002-present), Epilepsy Research (2007-present), European Journal of Pharmaceutical Sciences (1992-1998), Journal of Pharmaceutical Sciences (1990-1995) and Therapeutic Drug Monitoring (1999-present).**

**Dr. Bialer's research interests include: a) Pharmacokinetics of new antiepileptic drugs (AEDs) and pharmacokinetic-based design of new antiepileptics and CNS drugs. In this regard he has been utilizing structure pharmacokinetic pharmacodynamic relationship (SPPR) studies to design and develop new CNS drugs with better potency, lack of teratogenicity and a wide safety margin; b) Pharmacokinetic analysis of new drugs, sustained release dosage forms and novel drug delivery systems (DDS); c) Stereospecific pharmacokinetic and pharmacodynamic analysis of chiral drugs; d) Pharmacogenetics of CNS drugs; and e) Pharmacoresistance to AEDs. In these areas, he has 220 peer reviewed publications and is an author of numerous book chapters.**